Request Info...
... The Nick Translation System is ideal for ... The Nick Translation System: Provides five ... nucleotide incorporation Yields >10 8 ... control DNA to monitor the performance of ...
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products:(Date:12/16/2009)... University (NTU) signed the Memorandum of Understanding in ... (CNRS) and the Thales Group of Companies to ... parties are meeting again in Singapore to inaugurate ... , Located at the Research Techno Plaza, ... in science and technology to develop innovations in ...
(Date:12/16/2009)... Blood America, Inc. (OTC Bulletin Board: CBAI), the ... http://www.cordblood-america.com ) focused on bringing the life ... policy, to families nationwide and internationally, said today ... total of $1.4 million so far in the ... for the year now tops $10 million. ,, ...
(Date:12/16/2009)... Protocol Assessment with the Food and Drug ... - AEterna Zentaris Inc. (NASDAQ: AEZS ... biopharmaceutical company focused on oncology and endocrine ... partner Keryx Biopharmaceuticals Inc. ("Keryx") ( KERX), ... for perifosine (KRX-0401), the Company,s PI3K/Akt pathway ...
(Date:12/15/2009)... Calif., Dec. 15 Epeius Biotechnologies Corporation, ... genetic medicine, gained international validation of the cutting-edge ... , when scientists around the world rediscovered the ... major locus of cancer pathogenesis and disease progression, ... Recently, scientists at the NIH National Cancer Institute ...
Breaking Biology Technology:New Singapore-French nanotech lab opens at NTU 2New Singapore-French nanotech lab opens at NTU 3Cord Blood America Says 2009 Debt Reduction Tops $10 Million 2Cord Blood America Says 2009 Debt Reduction Tops $10 Million 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3Biology NavigationMedical Navigation